

Remarks

The amendment to claim 1 was made to correct a typographical error. Applicants point out that support for this amendment can be found in the specification as originally filed. Specifically, SEQ ID NO:9 is disclosed in the specification as rat sNgR310. *See* specification at page 27, lines 7-11 and Table 1. The specification indicates that SEQ ID NO:26 is a peptide fragment obtained from the trypsin peptide digest of sNgR310. *See* specification at page 53, lines 12-20. Additionally, SEQ ID NO:9 contains the threonine amino acid at position number 102. Thus, Applicants respectfully assert that it is clear that the missing amino acid (threonine) in SEQ ID NO:26 was a typographical error.

The amendments to the specification are also being made to correct the same typographical error.

Upon entry of the foregoing amendment, claims 1, 2, 4, 5, 7-10, 13-16, 18, 19, 22, 24, and 26-29 are pending in the application, with claim 1 being the independent claim. Claims 3, 6, 11, 12, 17, 20, 21, 23, and 25 are sought to be cancelled without prejudice to or disclaimer of the subject matter therein. Thus, these changes are believed to introduce no new matter, and their entry is respectfully requested.

Conclusion

Prompt and favorable consideration of this Preliminary Amendment is respectfully requested. Applicants believe the present application is in condition for examination. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Shannon A. Carroll, Ph.D.
Attorney for Applicants
Registration No. 58,240

Date: February 26, 2008
1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

754314_1.DOC